Details of the Drug

General Information of Drug (ID: DMG629M)

• Drug Name: Rivastigmine
• Synonyms: Rivastigmine (transdermal patch)

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Approved	[1], [2]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 250.34
  Topological Polar Surface Area (xlogp); 2.3
  Rotatable Bond Count (rotbonds); 5
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 3
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
  Bioavailability: 72% of drug becomes completely available to its intended biological destination(s) [4]
  Clearance: The renal clearance of drug is 2.1-2.8 L/h [5]
  Elimination: 0.1% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 hours [6]
  Metabolism: The drug is metabolized via the cholinesterase-mediated hydrolysis [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.7989 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.6% [6]
  Vd: The volume of distribution (Vd) of drug is 1.8-2.7 L/kg [5]
• Chemical Identifiers:
  Formula: C14H22N2O2
  IUPAC Name: [3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
  Canonical SMILES: CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C
  InChI: InChI=1S/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1
  InChIKey: XSVMFMHYUFZWBK-NSHDSACASA-N
• Cross-matching ID:
  PubChem CID: 77991
  ChEBI ID: CHEBI:8874
  CAS Number: 123441-03-2
  DrugBank ID: DB00989
  TTD ID: D0WY5Q
  ACDINA ID: D00602

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Modulator	[9]

Molecular Expression Atlas of This Drug

• The Studied Disease: Alzheimer disease
• ICD Disease Classification: 8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Acetylcholinesterase (AChE)	DTT	ACHE	6.39E-02	-1.07	-1.15

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Rivastigmine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Additive cholinergic effects by the combination of Rivastigmine and Bethanechol.	Abnormal micturition [MF50]	[19]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Midostaurin.	Acute myeloid leukaemia [2A60]	[20]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Idarubicin.	Acute myeloid leukaemia [2A60]	[20]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[20]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Oliceridine.	Acute pain [MG31]	[20]
Mepyramine	DMB4SFH	Moderate	Antagonize the effect of Rivastigmine when combined with Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[21]
Phenyltoloxamine	DMKAEQW	Moderate	Antagonize the effect of Rivastigmine when combined with Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[21]
Bedaquiline	DM3906J	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[20]
Cilostazol	DMZMSCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Cilostazol.	Arterial occlusive disease [BD40]	[20]
Posaconazole	DMUL5EW	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Posaconazole.	Aspergillosis [1F20]	[20]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Salbutamol.	Asthma [CA23]	[22]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Rivastigmine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[23]
Desipramine	DMT2FDC	Moderate	Antagonize the effect of Rivastigmine when combined with Desipramine.	Attention deficit hyperactivity disorder [6A05]	[24]
Ofloxacin	DM0VQN3	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Clarithromycin	DM4M1SG	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[20]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Gemifloxacin	DMHT34O	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Retigabine.	Behcet disease [4A62]	[20]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Eribulin.	Breast cancer [2C60-2C6Y]	[20]
Lapatinib	DM3BH1Y	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lapatinib.	Breast cancer [2C60-2C6Y]	[20]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Bosutinib.	Breast cancer [2C60-2C6Y]	[20]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[20]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[20]
Halothane	DM80OZ5	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Halothane.	Corneal disease [9A76-9A78]	[20]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sevoflurane.	Corneal disease [9A76-9A78]	[20]
Probucol	DMVZQ2M	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Probucol.	Coronary atherosclerosis [BA80]	[20]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Rivastigmine and Pasireotide.	Cushing syndrome [5A70]	[20]
Osilodrostat	DMIJC9X	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Osilodrostat.	Cushing syndrome [5A70]	[20]
Sertraline	DM0FB1J	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sertraline.	Depression [6A70-6A7Z]	[20]
Escitalopram	DMFK9HG	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Escitalopram.	Depression [6A70-6A7Z]	[20]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Rivastigmine when combined with OPC-34712.	Depression [6A70-6A7Z]	[24]
Clomipramine	DMINRKW	Moderate	Antagonize the effect of Rivastigmine when combined with Clomipramine.	Depression [6A70-6A7Z]	[24]
Doxepin	DMPI98T	Moderate	Antagonize the effect of Rivastigmine when combined with Doxepin.	Depression [6A70-6A7Z]	[24]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Rivastigmine when combined with Mepenzolate.	Digestive system disease [DE2Z]	[24]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Rivastigmine when combined with Oxybutynine.	Discovery agent [N.A.]	[24]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[20]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Deutetrabenazine.	Dystonic disorder [8A02]	[20]
Ingrezza	DMVPLNC	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ingrezza.	Dystonic disorder [8A02]	[20]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Rivastigmine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[24]
Solifenacin	DMG592Q	Moderate	Antagonize the effect of Rivastigmine when combined with Solifenacin.	Functional bladder disorder [GC50]	[24]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Rivastigmine when combined with Tolterodine.	Functional bladder disorder [GC50]	[24]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ketoconazole.	Fungal infection [1F29-1F2F]	[20]
Sunitinib	DMCBJSR	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[20]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Rivastigmine when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[24]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Rivastigmine when combined with ITI-007.	Insomnia [7A00-7A0Z]	[24]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Rivastigmine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[25]
Ceritinib	DMB920Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ceritinib.	Lung cancer [2C25]	[20]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Osimertinib.	Lung cancer [2C25]	[20]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Selpercatinib.	Lung cancer [2C25]	[20]
Lumefantrine	DM29GAD	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lumefantrine.	Malaria [1F40-1F45]	[22]
Halofantrine	DMOMK1V	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Halofantrine.	Malaria [1F40-1F45]	[20]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Hydroxychloroquine.	Malaria [1F40-1F45]	[20]
Primaquine	DMWQ16I	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Primaquine.	Malaria [1F40-1F45]	[20]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[20]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[20]
Vemurafenib	DM62UG5	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Vemurafenib.	Melanoma [2C30]	[20]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Rivastigmine and LGX818.	Melanoma [2C30]	[26]
Panobinostat	DM58WKG	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Panobinostat.	Multiple myeloma [2A83]	[20]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Thalidomide.	Multiple myeloma [2A83]	[22]
Siponimod	DM2R86O	Major	Increased risk of bradycardia by the combination of Rivastigmine and Siponimod.	Multiple sclerosis [8A40]	[22]
Fingolimod	DM5JVAN	Moderate	Increased risk of bradycardia by the combination of Rivastigmine and Fingolimod.	Multiple sclerosis [8A40]	[27]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Ozanimod.	Multiple sclerosis [8A40]	[28]
Neostigmine	DM6T2J3	Moderate	Additive cholinergic effects by the combination of Rivastigmine and Neostigmine.	Myasthenia gravis [8C6Y]	[19]
Edrophonium	DMCRQHB	Moderate	Additive cholinergic effects by the combination of Rivastigmine and Edrophonium.	Myasthenia gravis [8C6Y]	[19]
Ambenonium	DMOP0BL	Moderate	Additive cholinergic effects by the combination of Rivastigmine and Ambenonium.	Myasthenia gravis [8C6Y]	[19]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Romidepsin.	Mycosis fungoides [2B01]	[20]
Nilotinib	DM7HXWT	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[20]
Dasatinib	DMJV2EK	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[20]
Phenindamine	DMDTC7R	Moderate	Antagonize the effect of Rivastigmine when combined with Phenindamine.	Nasopharyngitis [CA00]	[24]
Promethazine	DM6I5GR	Moderate	Antagonize the effect of Rivastigmine when combined with Promethazine.	Nausea/vomiting [MD90]	[24]
Cyclizine	DM9G7BS	Moderate	Antagonize the effect of Rivastigmine when combined with Cyclizine.	Nausea/vomiting [MD90]	[24]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Rivastigmine and Bupropion.	Nicotine use disorder [6C4A]	[29]
Levomethadyl Acetate	DM06HG5	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[22]
Lofexidine	DM1WXA6	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lofexidine.	Opioid use disorder [6C43]	[20]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Rucaparib.	Ovarian cancer [2C73]	[20]
Flavoxate	DMKV4NL	Moderate	Antagonize the effect of Rivastigmine when combined with Flavoxate.	Pain [MG30-MG3Z]	[24]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Triclabendazole.	Parasitic worm infestation [1F90]	[20]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Pimavanserin.	Parkinsonism [8A00]	[20]
Orphenadrine	DMW542E	Moderate	Antagonize the effect of Rivastigmine when combined with Orphenadrine.	Parkinsonism [8A00]	[24]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Rivastigmine when combined with Methylscopolamine.	Peptic ulcer [DA61]	[24]
Macimorelin	DMQYJIR	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[20]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lefamulin.	Pneumonia [CA40]	[20]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Degarelix.	Prostate cancer [2C82]	[20]
Relugolix	DMK7IWL	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Relugolix.	Prostate cancer [2C82]	[20]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Rivastigmine when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[24]
Gatifloxacin	DMSL679	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[20]
Quetiapine	DM1N62C	Moderate	Antagonize the effect of Rivastigmine when combined with Quetiapine.	Schizophrenia [6A20]	[24]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Rivastigmine when combined with Aripiprazole.	Schizophrenia [6A20]	[24]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Iloperidone.	Schizophrenia [6A20]	[20]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Paliperidone.	Schizophrenia [6A20]	[20]
Molindone	DMAH70G	Moderate	Antagonize the effect of Rivastigmine when combined with Molindone.	Schizophrenia [6A20]	[24]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Rivastigmine when combined with Thiothixene.	Schizophrenia [6A20]	[24]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Asenapine.	Schizophrenia [6A20]	[20]
Pimozide	DMW83TP	Moderate	Antagonize the effect of Rivastigmine when combined with Pimozide.	Schizophrenia [6A20]	[24]
Vandetanib	DMRICNP	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[20]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Doxorubicin	DMVP5YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Pitolisant.	Somnolence [MG42]	[20]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[20]
Lenvatinib	DMB1IU4	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Lenvatinib.	Thyroid cancer [2D10]	[20]
Cabozantinib	DMIYDT4	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Cabozantinib.	Thyroid cancer [2D10]	[20]
Chlorpheniramine	DM5URA2	Moderate	Antagonize the effect of Rivastigmine when combined with Chlorpheniramine.	Vasomotor/allergic rhinitis [CA08]	[24]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Rivastigmine when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[21]
Acrivastine	DMTIGA0	Moderate	Antagonize the effect of Rivastigmine when combined with Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[24]
Propafenone	DMPIBJK	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[20]
Flecainide	DMSQDLE	Moderate	Increased risk of ventricular arrhythmias by the combination of Rivastigmine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[20]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hypromellose	E00634	Not Available	Coating agent
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Rivastigmine 1.5 mg capsule	1.5 mg	Oral Capsule	Oral
Rivastigmine 6 mg capsule	6 mg	Oral Capsule	Oral
Rivastigmine 3 mg capsule	3 mg	Oral Capsule	Oral
Rivastigmine 4.5 mg capsule	4.5 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6602).
• [2] ClinicalTrials.gov (NCT00948766) Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44. U.S. National Institutes of Health.
• [3] BDDCS applied to over 900 drugs
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [10] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [11] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [12] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [13] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [14] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [16] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [17] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [18] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [19] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [20] Canadian Pharmacists Association.
• [21] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
• [22] Cerner Multum, Inc. "Australian Product Information.".
• [23] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [24] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [25] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [26] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [27] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [28] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [29] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.